Vancouver, Jan. 16, 2024 (GLOBE NEWSWIRE) -- The global Intravenous (IV) solution market size was USD 8.0 Billion in 2022 and is expected to register a rapid revenue CAGR of 8.5% during the forecast period. Rising prevalence of immunodeficiency disease, increasing geriatric population, and rapid technological advancements in therapy are key factors driving market revenue growth.
The Need for IV solution is increasing as IV is used for, treating and preventing dehydration, electrolyte imbalances, and nutritional deficiencies. This is used to replenish fluids, electrolytes and provide nutrition. IV solution classified into two type nutrition, total parenteral and peripheral nutrition. Most significant advancements in IV solution market over the past year is development of smart IV pumps, which are designed to improve patient safety and reduce the risk of medication errors by automatically adjusting infusion rates based on patient weight, age, and medical condition.
Increasing prevalence of cancer and neurological disorders is another key factor driving revenue growth of the market. World Health Organization (WHO) estimates that 10 million deaths, or approximately one in six attributable to cancer in 2020, making it the leading cause of death worldwide. American Cancer Society estimated there are 1.9 million new cancer cases and 609,360 cancer deaths in 2022.The most common cancer were breast, lung, cervical, and prostate. Neurological disorders are the second leading cause of death globally, accounting for an estimated 9 million deaths each year. The most common neurological disorders that because death are stroke, Alzheimer’s Disease (AD). Unhealthy lifestyles, environmental factors, and ageing population are the main reasons of chronic disease.
A key market trend is rapid technological advancements in IV solution. The development of smart IV pumps, closed loop system, and nanoparticle-based IV solution. For instance, on 22 May 2023, Intellego Technologies and HAI Solutions partnered to improve the quality and safety of IV vascular access. This partnership combines Intellego's patented ultraviolet-sensitive ink as an indicator component with HAI Solutions QIKcap technology to provide visible and verifiable IV port protection. QIKcap is a disposable needle-free connector that is designed to prevent bacteria from entering the bloodstream, which is a simple and effective way to reduce the risk of infection,
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/2719
The high cost of therapy is a key factor, which could restrain market revenue growth. High cost of Intravenous therapy limits its use despite of increasing number of individuals with chronic diseases such as cancer and neurological diseases. This is especially true in low- and middle-income countries, where reimbursement policies for IV therapy are often limited. Rising demand for IV therapy and a captive market have allowed drug manufacturers to consistently raise prices, placing a significant financial burden on individuals and healthcare systems.
Segment Insights
Nutrition Insights:
On the basis of nutrition, the global IV solution market is segmented into amino acid solution, vitamin and mineral, carbohydrates, and others.
The amino acid solution segment is expected to account for significantly large revenue share in the global IV solution market during the forecast period due to prevalence of chronic liver disease. Journal of Hepatology estimated liver disease accounts for two million deaths annually and is responsible for 4% of all deaths (1 out of every 25 deaths worldwide), while approximately two-thirds of all liver-related deaths occur in men. PubMed estimated there are 1 million individuals affected due to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular carcinoma. National Institute of Diabetes and Digestive and Kidney Disease estimatedCirrhosis is an important cause of morbidity and mortality in people with chronic liver disease worldwide.
In addition, prevalence of cirrhosis steadily increases with age and reached at 0.57% in those between the ages of 45 to 54 years old. Amino acid solutions are commonly used in the treatment of liver for instance, on 23 April 2020, Baxter announced the U.S. Food and Drug Administration (FDA) approval of new formulations of Clinimix and Clinimix E for parenteral nutrition, also known as IV feeding, which are amino acid injections. These new Clinimix formulations contain up to 80 g/L of amino acids, the highest protein content in any multi-chamber bag available in the U.S. This allows clinicians to reach patient protein targets while delivering less fluid and dextrose than existing formulations more easily.
End user Insights:
The hospital segment is expected to account for largest revenue share in the global IV solution market during the forecast period. This is due to rising preference for early parenteral nutrition in critical care and liver cirrhosis and increasing prevalence of anemia and liver cirrhosis Hospitals offer a multidisciplinary approach to vitamin deficiency and chronic disease care.
Hospitals are the primary point of care for patients with vitamin deficiency diseases, which are the main indication for IV therapy. Patients and healthcare providers are increasingly preferring hospital-based care for IV therapy due to the convenience and safety it offers. In addition, hospitals have advanced medical facilities and expertise to administer IV therapy safely and effectively. Minimally invasive procedures, such as laparoscopic surgery and endoscopy, are becoming increasingly common in hospitals. These procedures required IV solutions to maintain hydration and provide nutritional support during recovery.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/2719
Regional Insights:
The North America market accounted for largest revenue share in the global IV solution market in 2022 due to increasing prevalence of chronic liver disease and cirrhosis. Center for Disease Control and Prevention (CDC) estimated there are 4.5 million and 1.8% adults diagnosed with liver cirrhosis and there are 56,585 individuals died due to liver disease.
In addition, key strategic initiatives as well as partnerships between major market companies developing IV solutions is also expected to drive market revenue growth of this region during the forecast period. For instance, on 13 November 2023, BioVie Pharmaceuticals, Inc. announced positive clinical results from a Phase 2b trial of BIV20 in Refractory as cites at the American Association for the Study of Liver Disease. This is a novel drug candidate for the treatment of refractory ascites in patients with cirrhosis. The results showed that BIV20 was significantly better than placebo at reducing ascites volume and improving patient-reported outcomes.
The Europe market is expected to register fastest revenue growth rate in the global IV solution market during the forecast period due to increasing prevalence of liver disease. The prevalence of liver cirrhosis in Europe ranges from 0.3% to 0.8%. Europe has a strong healthcare infrastructure with a well-trained workforce and access to advanced medical technologies. This makes it well-positioned to adopt new IV solutions and provide high-quality care to patients. In addition, increasing aging population in Europe, as adults are more likely to have chronic diseases that require IV therapy, is another factor driving market revenue growth of this region.
Scope of Research
| Report Details | Outcome |
| Market Size in 2022 | USD 8.0 Billion |
| CAGR (2023–2032) | 8.5% |
| Revenue Forecast To 2032 | USD 17.9 Billion |
| Base Year For Estimation | 2022 |
| Historical Data | 2019-2021 |
| Forecast Period | 2023–2032 |
| Quantitative Units | Revenue in USD Million and CAGR in % from 2023 to 2032 |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered | Type, nutrition, end-use, and region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
| Country Scope | U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Benelux, Rest of Europe, China, India, Japan, South Korea, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, and Rest of Middle East & Africa |
| Key Companies Profiled | Baxter International Inc., Ajinomoto Co., Inc., B. Braun Group, Pfizer, Grifols, FRESENIUS KABI, CSL Vifor, ICU Medical, Terumo Medical Corporation, and Otsuka |
| Customization Scope | 10 hours of free customization and expert consultation |
Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/2719
Major Companies and Competitive Landscape
The global IV solution market is fairly fragmented, with many large and medium-sized players accounting for the majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing a more effective IV solution product. Some major players included in the global IV solution market report are:
- Baxter International Inc.
- Ajinomoto Co., Inc.
- B. Braun Group
- Pfizer
- Grifols
- FRESENIUS KABI
- CSL Vifor
- ICU Medical
- Terumo Medical Corporation
- Otsuka
Strategic Development
- On 5 December 2022, Liquidia Corporation announced its partnership with Sandoz and Mainbridge Health to develop a new subcutaneous pump for administering Treprostinil Injection, a generic form of Remodulin. Treprostinil Injection is the first and only fully substitutable generic Treprostinil for parenteral administration. This generic form is offered to patients and physicians with the same level of service and support, but at a lower price than the branded drug.
- On 4 May 2022, Fresenius Kabi announced to acquire Ivenix, Inc. to expand its infusion therapy offerings in the U.S. Ivenix's cutting-edge infusion therapy platform complements Fresenius Kabi's existing portfolio, providing advanced hospital connectivity and interoperability solutions. This strategic move strengthens Fresenius Kabi's position in the infusion therapy market, offering a wider range of premium products to healthcare providers. The combination of Ivenix's hardware and software expertise with Fresenius Kabi's IV fluids and infusion devices creates a comprehensive and leading solution in the industry.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/intravenous-solution-market
For the purpose of this report, Emergen Research has segmented the global IV solution market on the basis of type, application, end-use, and region:
- Type Outlook (Revenue, USD Billion; 2019-2032)
- Total Parenteral Nutrition
- Peripheral Parenteral Nutrition
- Nutrition Outlook (Revenue, USD Billion; 2019-2032)
- Amino Acid Solution
- Vitamin and Minerals
- Carbohydrates
- Others
- End-Use Outlook (Revenue, USD Billion; 2019-2032)
- Hospitals
- Clinics
- Homecare
- Regional Outlook (Revenue, USD Billion; 2019-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of Middle East & Africa
- North America
Emergen Research is Offering Exclusive Customization as per your Specific Requirements@ https://www.emergenresearch.com/request-for-customization/2719
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights
